Guselkumab not checked

Johnson & Johnson (Janssen) · CNTO1959 · CNTO 1959

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
28 active
59 in total · 28 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“Guselkumab as prescribed by the participant's treating physician and obtained by the participant outside of the study per the treating physician's practice will be used.”In the company’s words, NCT07654751 on ClinicalTrials.gov
Tested for
Colitis, Ulcerative (6 trials), Arthritis, Psoriatic (5 trials), Crohn Disease (5 trials), Crohn's Disease (4 trials), Psoriasis (2 trials), Fistulizing Crohns Disease, Perianal Crohns Disease, Crohns Disease and 2 more
Main trialPhase 4
“The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.”In the company’s words, NCT04929210 on ClinicalTrials.gov
Other names
CNTO1959 · Tremfya · CNTO 1959

Other drugs for Colitis, Ulcerative

All 79 drugs for Colitis, Ulcerative

Coming up12

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials59

TrialPhaseCompletesWhat it tests
Phase 4Active, not recruiting 1 Apr 2027 A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
Phase 4Recruiting 5 Jun 2027 A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)
Phase 4Recruiting 31 Aug 2027 A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
Phase 4Recruiting 15 Sep 2027 A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)
Phase 3Active, not recruiting 4 Jul 2023 A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
Phase 3Active, not recruiting 19 Jul 2023 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
Phase 3Active, not recruiting 2 Apr 2024 A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Phase 3Active, not recruiting 30 Dec 2024 A Study of Guselkumab in Participants With Active Psoriatic Arthritis
Phase 3Active, not recruiting 10 Feb 2027 A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
Phase 3Active, not recruiting 25 Mar 2027 A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
Phase 3Active, not recruiting 8 Jun 2027 Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
Phase 3Recruiting 27 Oct 2027 A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Phase 3Recruiting 12 Jun 2028 A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Phase 3Recruiting 11 Aug 2028 A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
Phase 3Recruiting 15 Nov 2028 A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Phase 3Recruiting 12 Dec 2031 A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Phase 2/3Active, not recruiting 19 Sep 2023 A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
Phase 2/3Active, not recruiting 20 Oct 2023 A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
Phase 2Active, not recruiting 15 May 2025 A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
Phase 2Active, not recruiting 23 May 2025 A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
Phase 4Terminated 28 Jul 2023 Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis
Phase 4Completed 26 Sep 2023 A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis
Phase 3Completed 29 Sep 2015 A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
Phase 3Completed 1 Oct 2015 A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment
Phase 3Completed 28 Mar 2017 An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis
Phase 3Completed 6 Feb 2018 Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
Phase 3Completed 25 Feb 2019 A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis
Phase 3Completed 14 Mar 2019 A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
Phase 3Completed 11 Nov 2020 A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy
Phase 3Completed 2 Mar 2021 A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
Phase 3Completed 7 Mar 2022 A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis
Phase 3Terminated 29 Sep 2023 A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection
Phase 3Completed 29 Feb 2024 A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
Phase 3Completed 28 Oct 2024 Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
Phase 3Completed 14 Apr 2025 Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis
Phase 3Completed 30 May 2025 Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis
Phase 3Completed 12 Jan 2026 A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
Phase 2Completed 31 May 2016 Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)
Phase 2Completed 22 May 2020 A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
Phase 2Completed 1 Dec 2020 A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
Phase 2Terminated 1 Feb 2023 A Study of Guselkumab in Participants With Active Lupus Nephritis
Phase 2Completed 17 May 2023 A Study of Guselkumab in Participants With Systemic Sclerosis
Phase 2Completed 14 May 2024 A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis
Phase 2Terminated 22 May 2024 A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis
Phase 1Completed 12 Jan 2016 A Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Participants
Phase 1Completed 31 Dec 2020 Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants
Phase 1Completed 20 Jul 2021 A Study of Intravenous Formulation of Guselkumab Using Prefilled Syringes and Final Vialed Product in Healthy Participants
Phase 1Completed 13 Sep 2021 A Study of Guselkumab in Participants With Familial Adenomatous Polyposis
Phase 1Withdrawn 13 Sep 2021 A Study of Guselkumab in Adult Participants With Celiac Disease
Phase 1Completed 13 Sep 2021 A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants
Phase 1Terminated 1 Jul 2022 A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis
Phase 4Authorised not given Prevention of postoperative endoscopic recurrence with endoscopy-driven versus systematic biological therapy: a randomized, multicentre, parallel group pragmatic non-inferiority trial in adult patients with Crohn’s disease undergoing an ileocolonic resection with ileocolonic anastomosis
Phase 4Authorised not given AN INVESTIGATOR-INITIATED, PHASE 4, OPEN-LABEL, SINGLE-ARM, SINGLE-CENTER STUDY INVESTIGATING THE TISSUE-RESIDENT MEMORY T-CELLS AND DISEASE MEMORY IN PSORIASIS SKIN DURING GUSELKUMAB TREATMENT. THE GUSMEM STUDY.
Phase 3Authorised not given A prospective, randomized, controlled, open label, assessor-blinded, parallel-group Phase III clinical trial to evaluate the impact of tapering systemic immunosuppressive therapy in a treat-to-target approach on maintaining minimal disease activity in adult subjects with psoriatic arthritis
Phase 4Authorised not given Proactive therapeutic drug monitoring versus routine care with the novel biologics in psoriasis: a pragmatic, multicentric, randomised, controlled study (HELIOS)
Phase 4Authorised not given Prospective, multicentre, open-label clinical trial on the effect of GUSelkumab on the resolution of ultrasound-proven ENThEsitis in patients with pSoriatic arthriTis
Phase 4Authorised not given GUselkumAb inteRvention and DIet evaluAtioN for pouchitis
Phase 4Authorised not given Arthritis interception with Guselkumab in subclinical psoriatic arthritis patients in clinical transition from skin to joint disease: a randomized clinical trial.
Phase 4Authorised not given OPTIMAL CARE WITH GUSELKUMAB IN CROHN’S DISEASE
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Guselkumab

Following is part of Solo: you see every change to Guselkumab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in